AHR-16303B

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameAHR-16303B

Drug Alias NameAHR-16303B

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVoltage-gated calcium channel blockersSerotonin 2 (5-HT2) receptor antagonists

TargetsVoltage-gated calcium channelSerotonin 2 (5-HT2) receptor

Therapy Area/IndicationsHypertensionThrombosisMyocardial Ischemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsHypertensionThrombosisMyocardial Ischemia

ATC CodeN/A